Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
US9885021B2 · kind B2 · utility
10Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2015 |
| Grant date | Feb 6, 2018 |
| Priority date | — |
| Expiry date | Jun 11, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions for T cell-based immunotherapy of HIV, HIV-associated malignancies, HIV-associated viral infections, or other HIV-related complications. Modified T cells that are resistant to invasion or infection with HIV, such as T-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (“MOGS”). Methods for producing such compositions by expanding HIV-specific T cells from different sources to recognize multiple HIV antigens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.